Picture of AnaptysBio logo

ANABV — AnaptysBio News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMid CapHigh Flyer

AnaptysBio Inc expected to post a loss of $1.70 a share - Earnings Preview

* AnaptysBio Inc  ANAB.OQ   ANAB.O  is expected to show a
rise in
quarterly revenue when it reports  results on August 7
(estimated). 
    * The San Diego California-based  company is expected to
report  a
173.2% increase in revenue to $3.322 million from $1.22 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for AnaptysBio Inc is
for a
loss of $1.70 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for AnaptysBio
Inc is
$28.5​, above​ its last closing price of $19.11. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -1.08       -1.05      -1.58     Missed  -50.8
 Dec. 31 2023  -0.96       -0.96      -0.93     Beat    2.8
 Sep. 30 2022  -0.65       -0.72      -1.18     Missed  -63.1​
 Jun. 30 2022  -0.89       -1.02      -1.15     Missed  -12.6
 ​​Mar.        -1.02       -0.99      -1.31     Missed  -31.7
 31 2022                                                
 Dec. 31 2021  5.54        2.57       -1.13     Missed  -143.9
                                                        ​
 Sep. 30 2021  -0.93       -0.91      -0.24     Beat    73.6
 Jun. 30 2021  -0.11       -0.11      -0.02     Beat    81.3
 This summary was machine generated August 4 at 12:42 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on AnaptysBio

See all news